文献速递消化系统肿瘤

外显子组测序联合类器官培养指导胰胆管癌个体化治疗

Development of a system combining comprehensive genotyping and organoid cultures for identifying and testing genotype-oriented personalised medicine for pancreatobiliary cancers.
PubMed 文献 · Eur J Cancer · 2021-03-19

本研究旨在建立外显子组测序联合类器官培养系统,为胰胆管癌识别并测试基因型导向的靶向药物。54例切除肿瘤中30例(55.6%)类器官培养成功,6例胆道/胆囊癌外显子组测序揭示多种体细胞突变,类器官保留原发肿瘤组织病理和基因组特征,ILK抑制剂可抑制患者来源类器官增殖。

要点

  • 类器官培养成功率55.6%(30/54例胰胆管癌切除标本)。
  • 6例胆道/胆囊癌外显子组测序发现信号通路、表观遗传修饰、基因组维护和代谢酶相关基因体细胞突变。
  • ILK为候选靶点,ILK抑制剂可抑制患者来源类器官增殖。

核心结论

  • 外显子组测序联合类器官培养可识别胰胆管癌基因型导向的个体化治疗靶点并在类器官中测试候选靶向药物疗效。

研究设计与样本

  • 从切除肿瘤分离的肿瘤细胞按已发表方案改良后进行类器官培养,原发肿瘤行外显子组测序。
  • 在对应类器官中验证原发肿瘤的组织病理和分子特征,并从外显子组测序中识别基因型导向候选靶向药物后在类器官中测试其疗效。

主要发现

  • 54例中30例(55.6%)类器官培养成功。
  • 6例胆道和胆囊原发癌行外显子组测序,揭示信号通路、表观遗传修饰、基因组维护和代谢酶相关基因的多种体细胞突变。
  • 这6例中大多数类器官显示与原发肿瘤相同的组织病理特征和基因组异常。
  • 部分异常为靶向治疗候选,ILK为候选靶点之一,ILK抑制剂被证实可抑制患者来源类器官的增殖。

临床怎么用

  • 该概念验证方法可增加胰胆管癌患者的治疗机会。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Pancreatobiliary cancer is a highly aggressive tumour with a dismal prognosis. Personalised medicine represents a promising and effective therapeutic approach for this intractable disease. In this study, we aimed to establish a system for identifying and testing genotype-oriented targeted drugs for pancreatobiliary cancers by combining exome sequencing and organoid culture of primary tumours. METHODS: Tumour cells isolated from resected tumours were subjected to organoid cultures based on published protocols with modifications. Exome sequencing was performed on the primary tumours. Histopathological and molecular features of the primary tumours were validated in the corresponding organoids. Genotype-oriented candidate targeted drugs were identified from exome sequencing, and their efficacies were tested in the organoids. RESULTS: Organoid cultures succeeded in 30 of 54 (55.6%) cases. Six primary cancers of the biliary tract and gall bladder were subjected to exome sequencing, which revealed a variety of somatic mutations of genes involved in signalling pathways, epigenetic modifiers, genome maintenance and metabolic enzymes. Most of the organoids of these 6 cases showed identical histopathological features and genomic aberrations as those of the primary tumours. Some of the aberrations were candidates for targeted therapies. Integrin-linked kinase (ILK) was one such candidate target, and an ILK inhibitor was confirmed to suppress proliferation of patient-derived organoids. CONCLUSIONS: By combining exome sequencing and organoid culture, our model enabled to identify genotype-oriented targets for personalised medicine and to test efficacies of candidate targeted drugs in the organoids. The current proof-of-concept approach could increase therapeutic opportunities for patients with pancreatobiliary cancers.

来源:Eur J Cancer,查看原文。版权归原作者所有。

引用

  1. Shiihara M, Ishikawa T, Saiki Y, et al. Development of a system combining comprehensive genotyping and organoid cultures for identifying and testing genotype-oriented personalised medicine for pancreatobiliary cancers. Eur J Cancer. 2021. PMID: 33752134. doi:10.1016/j.ejca.2021.01.047

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。